Neural Control of Heart Rate Is an Arrhythmia Risk Modifier in Long QT Syndrome  by Schwartz, Peter J. et al.
A
u
t
p
v
s
s
F
o
t
M
A
I
M
b
C
Journal of the American College of Cardiology Vol. 51, No. 9, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PHeart Rhythm Disorders
Neural Control of Heart Rate Is an
Arrhythmia Risk Modifier in Long QT Syndrome
Peter J. Schwartz, MD, FACC,*†‡**†† Emilio Vanoli, MD,*¶ Lia Crotti, MD, PHD,*†‡
Carla Spazzolini, DVM,* Chiara Ferrandi, BSC,‡ Althea Goosen, BSC,** Paula Hedley, MSC,‡‡
Marshall Heradien, MD,** Sara Bacchini, MD,*† Annalisa Turco, MD,*†
Maria Teresa La Rovere, MD,# Antonella Bartoli, PHARMD,§ Alfred L. George, JR, MD,§§
Paul A. Brink, MD**
Pavia, Milan, Monza, and Montescano, Italy; Stellenbosch, and Cape Town, South Africa;
and Nashville, Tennessee
Objectives The purpose of this study was to test the hypothesis that differences in autonomic responses might modify clini-
cal severity in long QT syndrome type 1 (LQT1) patients, those with KCNQ1 mutations and reduced IKs, in whom
the main arrhythmia trigger is sympathetic activation.
Background Some long QT syndrome (LQTS) patients experience life-threatening cardiac arrhythmias, whereas others remain
asymptomatic throughout life. This clinical heterogeneity is currently unexplained.
Methods In a South African LQT1 founder population segregating KCNQ1-A341V, we correlated major cardiac events to
resting heart rate (HR) and to baroreflex sensitivity (BRS) on and off beta-adrenergic blockers (BB).
Results In 56 mutation carriers (MCs), mean HR was lower among asymptomatic patients (p  0.05). Among MCs with
a QT interval corrected for heart rate 500 ms, those in the lower HR tertile were less likely to have suffered
prior cardiac events (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.04 to 0.79, p  0.02). The BRS was
lower among asymptomatic than symptomatic MCs (11.8  3.5 ms/mm Hg vs. 20.1  10.9 ms/mm Hg, p 
0.05). A BRS in the lower tertile was associated with a lower probability of being symptomatic (OR 0.13, 95% CI
0.02 to 0.96, p  0.05). A similar trend was observed during BB. The MCs in the lower tertile for both HR and
BRS were less frequently symptomatic than MCs with different patterns (20% vs. 76%, p  0.05). Subjects with
either ADRA2C-Del322-325 or homozygous for ADRB1-R389, 2 polymorphisms predicting enhanced adrenergic
response, were more likely to have BRS values above the upper tertile (45% vs. 8%, p  0.05).
Conclusions Lower resting HR and “relatively low” BRS are protective factors in KCNQ1-A341V carriers. A plausible underlying
mechanism is that blunted autonomic responses prevent rapid HR changes, arrhythmogenic when IKs is re-
duced. These findings help understanding phenotypic heterogeneity in LQTS and identify a physiological risk
modifier, which is probably genetically determined. (J Am Coll Cardiol 2008;51:920–9) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.069(
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he same disease. For instance, why do almost 5% of
atients with an acute myocardial infarction (MI) develop
entricular fibrillation in the first few hours and often do not
urvive? A rational approach to this problem is to exploit
tudies of monogenic diseases. Long QT syndrome
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March 4, 2008:920–9 Autonomic Risk Modifiers for LQTSFounder populations provide the presence of the same
utation in a relatively large number of individuals, thus
llowing a comparison between mutation carriers (MCs)
ith and without clinical events (i.e., syncope, cardiac arrest,
udden death in the case of LQTS). Genotype-phenotype
tudies have revealed that, in the most common variant of
QTS—long QT syndrome type 1 (LQT1)—caused by
utations in KCNQ1 encoding the pore-forming subunit of
he delayed rectifier potassium current (slow) (IKs), most
ardiac events occur under conditions associated with aug-
ented sympathetic activity such as physical and emotional
tress (2). Indeed, mutations affecting IKs create an arrhyth-
ogenic substrate exquisitely vulnerable to adrenergic acti-
ation and to heart rate (HR) increases (3,4). The availabil-
ty of a well characterized South African LQT1 founder
opulation segregating KCNQ1-A341V and in which rest-
ng HR levels—assessed during a standard electrocardio-
ram (ECG)—seem associated with arrhythmic risk (1)
ffered the opportunity to test our hypothesis that the
utonomic nervous system could act as an arrhythmia risk
odifier in LQTS (5).
We had provided experimental (6) and clinical (7) evidence
hat alterations in the autonomic control of the heart, high-
ighted by depressed baroreflex sensitivity (BRS)—largely a
arker of reduced cardiac vagal activity—are associated with
ncreased risk for arrhythmias and sudden death after an MI.
he wide distribution of BRS values in normal animals (6)
uggested that these and other autonomic responses are under
t least partial genetic control (8).
To define whether individual differences in autonomic
esponsiveness are associated with a higher or lower pro-
ensity for life-threatening arrhythmias, we assessed tonic
nd reflex control of HR in the South African LQT1
ounder population by determining resting HR and BRS.
e specifically tested the hypothesis that MCs with life-
hreatening arrhythmias would have had, as post-MI pa-
ients, lower BRS values compared with asymptomatic
arriers. We also considered the possibility that indepen-
ently transmitted functional polymorphisms of selected
drenergic receptors might contribute to BRS values, thus
nteracting with the KCNQ1-A341V mutation and increas-
ng or decreasing arrhythmic risk.
ethods
tudy population. We focused on an LQT1 founder
opulation harboring an identical LQTS-causative muta-
ion in KCNQ1 (A341V) (1). Clinical and genetic data were
ecorded on specifically designed forms including demo-
raphic information, personal and family history of disease,
ymptoms, and therapy. Cardiac events were defined as
yncope (fainting spells with transient but complete loss of
onsciousness) or aborted cardiac arrest (requiring resusci-
ation). The MCs were classified as either symptomatic or
symptomatic on the basis of their history of cardiac events.
ymptomatic subjects were MCs who had experienced at Hny time in the past at least 1
ardiac event irrespective of ther-
py, whereas to be defined
symptomatic an MC had to be
t least 20 years old and without
rior cardiac events off therapy.
herefore, throughout the text,
risk” is used to define the asso-
iation between specific parame-
ers and probability of having
uffered cardiac events at any
ime in the past. A QT interval
orrected for heart rate (QTc)
500 ms was regarded as indi-
ating a major arrhythmogenic
ubstrate (1,9).
All probands and family mem-
ers provided written informed
onsent for clinical and genetic evaluations, as approved by
he ethical review boards of the Stellenbosch, Vanderbilt,
nd Pavia universities.
enotyping. Peripheral blood was collected from all index
ases and family members entered in the study. From
enomic deoxyribonucleic acid (DNA) the A341V muta-
ion was detected through polymerase chain reaction and
estriction digestion (1).
Adrenergic receptor gene polymorphisms were screened
y different techniques. The ADRB1-S49G, ADRB1-
389R, ADRB2-R19C, ADRB2-R16G, ADRB2-Q27E,
DRB2-T164I, ADRB3-W64R, and ADRA1A-R492C
ere evaluated with the TaqMan 5’ nucleotidase assay (ABI
rism 7900HT, Applied Biosystems, Foster City, Califor-
ia), and one-third of cases were randomly selected for
alidation by restriction fragment-length polymorphism
RFLP) methods. The ADRA2B-Del301-303 and
DRA2C-Del322-325 were evaluated by denaturing high-
erformance liquid chromatography analysis (Wave model
500HT, Transgenomic, Omaha, Nebraska), and one-third
f cases were randomly validated by RFLP methods.
utonomic evaluation. All subjects were either hospital-
zed or stayed in a hotel close to Tygerberg Hospital for 4
ays to be studied both on and off beta-adrenergic blockers
BB). Plasma concentrations of propranolol and atenolol
ere determined by high-performance liquid chromatogra-
hy with fluorometric detection. Plasma levels below 20
g/ml were considered “nontherapeutic.”
easurement of HR and BRS. Parameters of time- and
requency-domain HR variability (10) were calculated after
nvironmental acclimation, while the subjects were resting
omfortably. The ECG, blood pressure, and respiratory
ctivity were simultaneously recorded for a 10-min period,
igitized, and stored by a PC-based software system (Ans-
ab, Bioengineering Service Montescano, Italy).
The BRS was determined by the phenylephrine method,
elating a transient increase in blood pressure (20 to 30 mm
Abbreviations
and Acronyms
BB  beta-adrenergic
blockers
BRS  baroreflex
sensitivity
CI  confidence interval
ECG  electrocardiogram
HR  heart rate
IKs  delayed rectifier
potassium current (slow)
LQT1  long QT syndrome
type 1
LQTS  long QT syndrome
MC  mutation carrier
OR  odds ratiog) induced by bolus injections of phenylephrine (2 to 3
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Autonomic Risk Modifiers for LQTS March 4, 2008:920–9g/kg, as necessary) to the resultant lengthening of the RR
nterval (11,12). The slope of a best-fit regression line
efined BRS. Beat-to-beat RR interval and blood pressure
ere continuously recorded (FINAPRES, Ohmeda, Engle-
ood, New Jersey) and then digitally converted. The BRS
as calculated by 2 experienced investigators (E.V. and
.T.L.R.) blinded to each other’s measurements.
Age has an important influence on BRS (12), and
ndeed in the 75 subjects under study whose age range
as 16 to 65 years, there was a significant (p  0.001)
egative correlation between age and BRS (r  0.67).
ccordingly, we focused our analysis on the second and
hird age quartiles that included 38 subjects (age 26 to 47
ears) and represented the middle 50% of the tested
opulation. In this group the correlation with age was not
ignificant (see the Results section). This approach al-
owed a reliable assessment of BRS while controlling for
he age effect.
tatistical analysis. Continuous variables are presented as
ean  SD and compared by Student t test or Mann-
hitney U test as appropriate, without adjustment for
ultiple comparisons. The relationships of BRS with age
nd HR were analyzed by nonparametric Spearman corre-
ations. Categorical variables were expressed as absolute and
elative frequencies and were compared by the Fisher exact
est or chi-square test. The change in HR and in BRS values
roduced by BB was evaluated by the paired-samples t test
rocedure or by the Wilcoxon signed rank test. To deter-
ine the association of HR and BRS with the occurrence of
ardiac events in the population under study, these variables
ere divided into tertiles of their respective distribution.
Figure 1 Study Population and Outline of the Study
Flow chart of the study population showing the number of subjects, divided in sub
beta-adrenergic blockers (BBs). For the study on BB, the number of subjects was l
for paired comparisons. BRS  baroreflex sensitivity; HR  heart rate; MC  mutnadjusted odds ratios (ORs) with 95% confidence intervals
CIs) were estimated by logistic regression. A 2-sided p
alue 0.05 was considered statistically significant. All
nalyses were performed with SPSS software (version 12,
PSS Inc., Chicago, Illinois).
esults
igure 1 explains the relationship between the current group
f study subjects (n  83) and the previously reported
opulation (1). Heart rate data were available for all sub-
ects, but some did not complete the BRS study either on or
ff BB for various reasons.
nfluence of HR on symptoms. Figure 2A illustrates that
esting HR off BB was no different between the 56 MCs (41
ith and 15 without symptoms) and the 27 non-MCs (65
9 beats/min vs. 68  9 beats/min, p  0.08). Similarly,
here was no difference when we compared only symptom-
tic MCs to non-MCs (66  9 beats/min vs. 68  9
eats/min, p  NS). By contrast, a significant difference
merged when we compared asymptomatic and symptom-
tic MCs: asymptomatic MCs had a significantly lower HR
61 8 beats/min vs. 66 9 beats/min, p 0.038) (Fig. 2B).
The same analysis was repeated in 50 subjects (38 MCs
nd 12 non-MCs) during BB. Treatment reduced HR by 9
6 beats/min (p  0.001). When examined separately for
on-MCs, symptomatic MCs, and asymptomatic MCs, the
esults resembled the findings observed in the absence of
B. The MCs and non-MCs had similar HR values (55 
beats/min vs. 57  9 beats/min, p  NS), but the
symptomatic MCs (n  11) had a significantly lower HR
by genetic status, considered in the different analyses performed on and off
to those with both measurements—on- and off-treatment—available, allowing
arriers; N.M.C.  nonmutation carriers; SA  South African; WO  Wash-Out.groups
imited
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March 4, 2008:920–9 Autonomic Risk Modifiers for LQTSompared with the 27 symptomatic MCs (51  11 beats/
in vs. 57  8 beats/min, p  0.05).
We assessed whether the level of resting HR was associ-
ted with a history of arrhythmic events in the subgroup of
atients with a QTc 500 ms and found that MCs in the
rst tertile (HR 60 beats/min) were less frequently symp-
omatic compared with MCs in the other 2 tertiles (OR
.19, 95% CI 0.04 to 0.79, p 0.023) (Fig. 3). Figure 3 also
rovides evidence that a QTc 500 ms represents a more
evere arrhythmogenic substrate in our population, on the
asis of the fact that 15 of 16 (94%) MCs with a QTc500
s were symptomatic.
Heart rate variability, both in time- (SDNN) and
requency-domain (LF/HF), was no different between
symptomatic and symptomatic MCs (45  19 ms vs. 36 
7 ms, and 1.5  1.2 ms vs. 1.4  1.4 ms, respectively).
RS and risk for cardiac events. The analysis of BRS was
imited to subjects in the 2 middle age quartiles (26 to 47
ears) to avoid the influence of age (see Methods). Indeed,
ithin this group (n 38) there was no correlation between
RS and age (r  0.17, p  NS). Furthermore, even
Figure 2 Heart Rate Values
Comparison of resting heart rate mean values off BB therapy between mutation
carriers (MCs) and non-MCs (A) and between asymptomatic and symptomatic
MCs (B). bpm  beats/min; other abbreviations as in Figure 1.ubdividing this group according to the median value (36ears), there was no difference in BRS across the 2
ubgroups.
The mean value of BRS in the entire group of 38 subjects
as 16.7  8.8 ms/mm Hg (Fig. 4A). As expected by a
istribution of autonomic parameters independent of the
QTS mutation, the BRS values between MCs (n  22)
nd non-MCs (n  16) were no different (17.1  9.7 vs.
6.3  7.6, p  NS) (Fig. 4B). By contrast, a significant
ifference emerged when the analysis compared the asymp-
omatic (n  8) with the symptomatic (n  14) MCs (11.8
3.5 vs. 20.1  10.9; p  0.05) (Fig. 4C).
A BRS 12 ms/mm Hg, which corresponds to the first
ertile of the distribution among all the 38 subjects, was
ssociated with a significantly lower probability of having
uffered cardiac events compared with a BRS in the upper 2
ertiles (OR 0.13, 95% CI 0.02 to 0.96, p 0.05) (Fig. 4C).
ndeed, among MCs with a BRS12 ms/mm Hg, 10 of 12
83%) subjects were symptomatic. The BRS values in the
rst tertile, which represents the lower end of the spectrum
f normal values among these South African families, will
e referred to as “relatively low.”
When we assessed whether the level of BRS was associ-
ted with a history of cardiac events in the 15 patients with
QTc500 ms, we found that none of the MCs in the first
ertile (BRS 12 ms/mm Hg) had cardiac events, whereas
0% of those with a BRS 12 ms/mm Hg were symptom-
tic (p  0.01) (Fig. 5).
In 22 of these 38 subjects we assessed BRS both on and
ff BB and observed that treatment significantly increased
Figure 3 Differential Risk for Arrhythmic
Events According to Resting HR
Differential risk for arrhythmic events among MCs according to resting heart
rate (HR) off BB and QTc. The dashed horizontal line represents the predefined
cut-off for QTc ( or 500 ms), whereas the dashed vertical line corresponds
to the first tertile (60 beats/min) of the HR values distribution. Among the 56
mutation carriers included in the analysis of resting HR in the absence of BB,
1 symptomatic patient had a nonmeasurable QTc because of right bundle
branch block. QTc  QT interval corrected for heart rate; other abbreviations as
in Figures 1 and 2.
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Autonomic Risk Modifiers for LQTS March 4, 2008:920–9RS by 5  8 ms/mm Hg (p  0.05). Interestingly,
hereas a trend for greater BRS during BB therapy was
vident in both symptomatic MCs and non-MCs (4.5  7
nd 9  11 ms/mm Hg, respectively), it was practically
bsent in asymptomatic subjects (0.8  7 ms/mm Hg).
mong MCs on BB treatment and with a BRS above the
ower tertile (14 ms/mm Hg), 7 of 8 (87.5%) subjects had
ymptoms. Therefore, both off and on BB, having a BRS
bove the lower tertile was significantly associated with a
ositive history of cardiac events.
Baroreflex sensitivity was not correlated with resting HR
r0.08), as expected (13). Given this lack of correlation,
e explored the association between the presence of rela-
ively low values of both HR and BRS and history of cardiac
A
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Figure 4 BRS Values
BRS values off-BB in the entire group under study ages 26 to 47 years (A), in
MCs and in non-MCs (B), and in symptomatic and asymptomatic MCs (C).
Mean and SD are shown for each subgroup. The dashed horizontal line repre-
sents the lower tertile of BRS values. CI  confidence interval; other abbrevia-
tions as in Figures 1 and 2.vents. Figure 6 shows that, across the 4 possible combina-ions of the 2 parameters, the smallest proportion (20%) of
ymptomatic subjects was found among MCs in the lower
ertile for both HR (60 beats/min) and BRS (12
s/mm Hg). This frequency, increasing to 60%, 75%, and
p to 87.5% when both BRS and HR were above the
orresponding cut-off, was significantly (p  0.05) lower
han for all other subjects combined.
nfluence of adrenergic receptor polymorphisms. Adren-
rgic receptor gene polymorphisms were screened and
orrelated with BRS values. The analyses were limited to 36
ubjects in the 2 middle-age quartiles for whom DNA was
vailable. We considered MCs (n 21) and non-MCs (n
5) together, because we expected their BRS to be inde-
endent of their mutation carrier status.
Although most of these polymorphisms had no signifi-
ant correlation with BRS values, ADRA2C-Del322-325
nd ADRB1-G389R revealed intriguing and significant
esults.
Del322-325 is a polymorphism of the alpha-2 adren-
rgic receptor gene. In the South African population the
inor allele frequency was 6.4%, no homozygous subjects
or the deletion were identified, and no deviation from
ardy-Weinberg equilibrium was observed. Subjects
ith ADRA2C-Del322-325 had higher BRS values com-
ared with subjects without the deletion (24.9  13.4
s/mm Hg vs. 15.8 7.5 ms/mm Hg, p 0.05); however,
ll of them were also carriers of ADRB1-G389R, a well
nown 1 adrenergic receptor polymorphism. To test the
ffect of ADRB1-G389R independently from ADRA2C-
el 322-325, we determined BRS values in subjects not
arrying this deletion. The BRS was 7.6 0.04 ms/mm Hg
n subjects homozygous for G389 (n  2), 14.8  12
s/mm Hg in the heterozygous (n  10), and 17.1  6.9
Figure 5 Differential Risk for Arrhythmic Events
According to BRS in MCs With a QTc <500 ms
The BRS and differential risk for arrhythmic events among MCs ages 26 to 47
years with a QTc 500 ms. The dashed vertical line corresponds to the lower
tertile (12 ms/mm Hg) of BRS values distribution. Abbreviations as in Figures
1, 2, and 3.
m
A
a
G
8
h

i
t
g
A
m
t
A
(
w
A
r
b
f
w
T
a
t
D
T
e
i
t
r
m
m
w
g
t
w
a
c
a
v
s
t
m
p
w
a
q
(
e
v
q
a
d
925JACC Vol. 51, No. 9, 2008 Schwartz et al.
March 4, 2008:920–9 Autonomic Risk Modifiers for LQTSs/mm Hg in the subjects homozygous for R389 (n  19).
mong these 3 genotypes, the frequency of BRS values
bove the upper tertile increased progressively from 0% in
389 to 10% in G389R, to 37% in R389, and jumped to
0% in subjects in whom G389R (homozygous for R and
eterozygous) is associated with ADRA2C-Del322-325 (p
0.05) (Fig. 7).
Because ADRA2C-Del322-325 is associated with an
ncreased release of norepinephrine from cardiac sympa-
hetic nerves and because ADRB1-R389 is associated with a
reater ability to couple to adenylyl cyclase than does
DRB1-G389, we hypothesized that the 2 receptor poly-
orphisms could act synergistically to modify BRS. To test
his hypothesis we combined subjects heterozygous for
DRA2C-Del322-325 or homozygous for ADRB1-R389
Group 1, 11 families) and compared them with subjects
ithout ADRA2C-Del322-325 and not homozygous for the
DRB1-R389 allele (Group 2, 7 families). Adrenergic
esponses were predicted to be enhanced in Group 1 and
lunted in Group 2. Group 1 subjects had a higher
requency of BRS values above the upper tertile compared
ith Group 2 subjects (46% vs. 8%; p  0.05) (Fig. 8).
hus, subjects with a genetic profile predicted to have
ugmented adrenergic responses had more brisk barorecep-
Figure 6 Impact on Arrhythmic Risk of HR and BRS
The BRS and resting HR off BB in the entire group ages 26 to 47 years. Differ-
ential probability of being symptomatic among MCs according to the combina-
tion of both BRS and HR values below or above the predefined cut-off. The
gray quadrant represents the distribution of symptomatic and asymptomatic
patients with relatively lower BRS (12 ms/mm Hg) and HR (60 beats/min)
values in comparison with the other permutations of the 2 autonomic markers.
The percentage of symptomatic MCs increases from 20% to 87.5%. Abbrevia-
tions as in Figures 1 and 2.or reflexes.iscussion
he present study tested the hypothesis (5) that the differ-
nt clinical severity observed among family members carry-
ng the same LQT1 mutation might be due to variations in
he autonomic control of HR, possibly of genetic origin. To
educe the possibility of chance observations, we studied
embers of a founder population all carrying the same
utation (KCNQ1-A341V); we focused on the age group in
hich autonomic responses were not influenced by age; and,
iven the potentially confounding role of BB, we performed
he study both on and off treatment.
Our hypothesis was that a reduced or relatively low BRS
ould have been associated with a greater probability of
rrhythmic events. This is the pattern that predicts in-
reased arrhythmic and mortality risk after an MI (6,7). We
ctually found that, contrary to our expectations, lower BRS
alues were associated with a lower probability of being
ymptomatic.
There is, however, a plausible biological explanation for
his finding. LQT1 subjects are at greatest risk for arrhyth-
ias whenever HR changes too rapidly, at variance with
atients affected by ischemic heart disease who are at risk
hen there is insufficient vagal activity to antagonize the
rrhythmogenic sympathetic activity. When HR increases
uickly, reduced IKs prevents the necessary QT adaptation
QT shortening) and a new ventricular depolarization might
ncroach the vulnerable phase of the T-wave, thus initiating
entricular tachycardia or fibrillation. When HR decreases
uickly, the sudden RR lengthening might increase the
mplitude of early after-depolarizations and initiate torsades
e pointes through triggered activity. This is why for LQT1
Figure 7 BRS Values in MCs and Non-MCs According to
Presence of ADRA2C-Del322-325 and ADRB1-G389
The BRS values in MCs and non-MCs ages 26 to 47 years. Groups A, B, and
C: subjects without ADRA2C-Del322-325. Group A: subjects homozygous for
ADRB1-G389. Group B: subjects heterozygous for ADRB1-G389R. Group C:
subjects homozygous for ADRB1-R389. Group D: subjects with ADRA2C-
Del322-325 (2 also heterozygous and 3 also homozygous for ADRB1-R389).
Abbreviations as in Figures 1 and 2.
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Autonomic Risk Modifiers for LQTS March 4, 2008:920–9ubjects a “blunted” autonomic response, as revealed by
elatively low BRS, acts as protective factor.
R is an arrhythmia risk modifier. In this South African
ounder population we recently observed that faster HRs
ere associated with a greater risk for cardiac events (1).
hat finding called attention for the first time to the
ossibility that resting HR might carry prognostic informa-
ion in LQTS. This information, however, was limited by
aving been derived from a standard ECG recorded in an
ncontrolled environment. In this study we assessed HR for
longer period of observation under true resting conditions.
eart rate variability did not seem to distinguish between
ymptomatic and asymptomatic individuals. This did not
urprise us, because we had already shown in different
atient populations that measures of “tonic” autonomic
ctivity could be much less informative than measures of
reflex” autonomic activity (10,14). Furthermore, this
oint had been proven in experiments involving direct
eural recordings of single cardiac vagal fibers destined to
he sinus node and not just surrogate markers of autonomic
ctivity such as any measure derived from HR (15).
The present results demonstrate that asymptomatic MCs
ad a significantly lower HR than symptomatic MCs. This
as true with and without BB. Because all but 1 of the
atients with a QTc 500 ms had symptoms (Fig. 3), we
ocused on those with a less severe arrhythmogenic substrate
i.e., QTc 500 ms), and it then became evident that those
n the lower tertile of HR were more frequently asymptom-
tic. Thus, the efficacy of BB in LQT1 patients is likely to
epend on 2 mechanisms of action: the direct antiadrenergic
ffect that antagonizes arrhythmia triggers (2) and the
Figure 8 BRS Values in MCs and Non-MCs According to the
Presence or Absence of Adrenergic Polymorphisms
The BRS values off-BB in subjects ages 26 to 47 years (MCs and non-MCs),
according to the specific genotype. Group 1: subjects with the ADRA2C-Del322-
325 and subjects homozygous for ADRB1-R389, polymorphisms resulting in
increased adrenergic responses. Group 2: subjects without ADRA2C-Del322-
325 and not homozygous for the ADRB1-R389 allele. The solid horizontal line
represents the upper tertile of BRS values. Abbreviations as in Figures 1 and 2.revention of fast HRs. pRS and cardiac events. We focused our study on the
econd- and third-age quartiles, providing ourselves with a
roup without influence of age on BRS, and despite a
educed sample size, the main differences observed were
tatistically significant.
Among healthy dogs the distribution of BRS values,
hich carries prognostic value in relation to the outcome
uring a first MI (6), has a wide range suggesting a genetic
nfluence (8). The present data show a similar distribution
n humans and especially no difference between MCs and
on-MCs, which is exactly what one would expect for 2
enetic traits independently transmitted. However, when
he analysis focused on the MCs it became evident that the
symptomatic carriers had significantly lower BRS values
ompared with MCs who suffered cardiac events. Besides
he sheer numerical difference in BRS values lies a finding of
eaningful prognostic significance.
Indeed, those MCs who have a BRS value in the lower
ertile (12 ms/mm Hg) were markedly less likely to be
ymptomatic with an OR of 0.13. Furthermore, when the
nalysis was restricted to those with a less severe arrhyth-
ogenic substrate (QTc 500 ms), the observed frequency
f symptomatic patients was dependent on the level of BRS.
n addition to the fact that none of the MCs in the lower
ertile for BRS had symptoms, it is worth noting (Fig. 5)
hat the only 2 asymptomatic patients with a BRS 12
s/mm Hg also had borderline QTc prolongation (445 and
54 ms). This suggests that within these South African
amilies, when the substrate is not overwhelmingly ar-
hythmogenic (QTc 500 ms), there are 2 distinct
atterns observed in asymptomatic MCs: either relatively
ow BRS even with a prolonged QTc (490 to 500 ms), or
RS 12 ms/mm Hg and a near-normal QTc. The same
orrelation between BRS values and clinical status per-
isted in the presence of BB.
These BRS values are not low; they are just “relatively
ow,” because they represent the lower end of the normal
istribution and might be regarded as a sign of a somewhat
iminished reflex autonomic activity.
An additional observation further supports the concept of
he autonomic background contributing importantly to the
rrhythmic profile in these LQT1 families. The lack of
orrelation between BRS and HR has allowed us to mean-
ngfully compare the MCs with lower values for both these
arameters and all other subjects together. Despite the small
ample size, the percentage of symptomatic patients in the
ower tertiles for both HR and BRS was significantly lower
20% vs. 76%).
Altogether, these data provide evidence that the individ-
al autonomic make-up effectively contributes to modulate
he probability of being symptomatic or asymptomatic in
atients with the KCNQ1-A341V mutation. This likely
pplies to other LQT1 subjects, but a specific study in
QT1 patients with different mutations will be necessary to
rove this point.
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March 4, 2008:920–9 Autonomic Risk Modifiers for LQTSnderlying mechanisms. Our objective was to test
hether autonomic responses could modulate the arrhyth-
ic history in members of a LQT1 founder population. We
easoned that, given the identical genetic arrhythmogenic
ubstrate (1) represented by subjects carrying the same
utation, there was a unique opportunity to assess whether
he arrhythmic profile is influenced by BRS values. On the
asis of our previous findings in post-MI dogs and patients,
e assumed that low BRS would have predicted increased
isk. Our data indicated that the opposite was true.
The reason for this striking difference, besides the afore-
entioned effect of an impaired IKs on QT shortening
uring tachycardia, lies in the fact that whereas strong vagal
eflexes might be life-saving in ischemic heart disease
16,17), they could actually precipitate torsades de pointes
n LQT1 subjects, because sudden pauses elicit early after-
epolarizations in LQTS. Thus, those LQT1 patients who
ave blunted autonomic responses, indicated by relatively
ow values of BRS, are less frequently symptomatic. There-
ore, a reduced ability to change HR suddenly, detrimental
or most individuals, is favorable and protective when
ombined with an impaired IKs, as in LQT1 patients.
Our ability to study several of these patients on and off
B provided additional mechanistic insights. Therapy with
B drugs increases BRS, but what we did not anticipate was
he striking difference between symptomatic and asymp-
omatic patients in their response to BB therapy. Whereas
ymptomatic MCs increased their BRS value by almost 5
s/mm Hg on BB, asymptomatic carriers had practically no
hange in BRS. This happened despite the fact that the
aseline values were higher among symptomatic MCs. This
nexpected finding indicates that asymptomatic carriers
ave a modest resting autonomic activity (a protective factor
or these patients), so that BB therapy can only slightly
odify autonomic balance. It also suggests another plausible
nderlying mechanism: namely, that symptomatic LQT1
atients might have enhanced basal sympathetic activity.
his would be reflected in slightly faster HRs and in higher
RS values, as measured by the phenylephrine method
11,12), because of the synergistic effect of the withdrawal of
he enhanced basal sympathetic tone coupled with the reflex
agal activation.
enetic risk modifiers. The search for genetic and phys-
ological modifiers of arrhythmic risk in LQTS and in other
isorders associated with sudden cardiac death is one of the
ost exciting challenges facing contemporary cardiology
18), but progress in this area has been limited.
We (19) and others (20) had indicated that LQTS
atients who were carriers of 2 independent mutations had
ncreased clinical severity. Thus, a second mutation could
ct as a modifier. However, the inherent rarity of 1 more
QTS mutation occurring in LQTS patients argued against
ompound mutations being a common type of genetic
odifier.
In 2005 we showed that a very common polymorphism,
CNH2-K897T, could amplify the electrophysiological ionsequences of a mutation with a modest effect on the IKr
urrent (21). That study indicated that common polymor-
hisms can act as genetic modifiers of clinical severity in
amilial arrhythmogenic disorders.
The present study carries the search for arrhythmia
odifiers in a novel direction. In LQT1 patients, for whom
he main arrhythmogenic trigger is sympathetic activation
2), it was reasonable to postulate a relation between
utonomic responses and arrhythmic risk (5). Baroreflex
ensitivity, a validated quantitative marker of autonomic
esponses, is partly under genetic control (22). We assumed
hat the wide range of BRS among individuals without
tructural heart disease could reflect this genetic control and
hat unavoidably also the carriers of LQT1 mutations would
nd themselves genetically bound to a propensity for having
low, intermediate, or high BRS. Our study suggests that
he outcome of this association by chance between LQT1
utations and varying levels of BRS would be a differential
robability of being symptomatic. Thus, the evidence
hat a specific autonomic phenotype (i.e., relatively low
RS) is associated with a reduced clinical severity of an
QT1 mutation indicates that genes controlling BRS or,
ore broadly, autonomic responses involved in the neural
ontrol of the heart might include key modifier genes that
ight increase or reduce the risk for sudden cardiac death
n LQTS and perhaps in other more common disorders
18,21).
These considerations provided the rationale for exploring
he “adrenergic cascade,” upstream and downstream, to
ssess the presence of polymorphisms that might modify
ither the amount of norepinephrine released at ventricular
evel or the sensitivity of the adrenergic receptors to cat-
cholamines. We screened our LQT1 population for func-
ional alpha- and beta-adrenoreceptor polymorphisms and
ound specific correlations with BRS values. Because BRS is
nfluenced by age and not by the KCNQ1-A341V mutation,
he analyses were performed both in MCs and non-MCs in
he 2 middle-age quartiles. The most interesting results
ame from 2 functional polymorphisms: ADRA2C-Del322-
25, and ADRB1-G389R.
The polymorphism of the alpha-2C adrenoreceptor con-
ists of a 12-base pair (bp) in-frame deletion causing a
ubstantial loss of agonist-mediated receptor function (23)
hat results in a loss of normal synaptic autoinhibitory
eedback and thereby in enhanced presynaptic release of
orepinephrine (24). In our South African population this
eletion was associated with greater BRS values and, there-
ore, with increased autonomic reactivity, consistent with
he increased release of norepinephrine induced by the
eletion. Indeed, norepinephrine released from sympathetic
fferent nerves enhances the baroreceptor reflex by sensitiz-
ng the receptor nerve endings (25).
Norepinephrine release from cardiac sympathetic nerves
ctivates myocyte 1-adrenergic receptors that couple to the
timulatory G protein (Gs), activating adenylyl cyclase and
ncreasing intracellular cAMP, thus augmenting cardiac
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Autonomic Risk Modifiers for LQTS March 4, 2008:920–9notropy, lusitropy, and chronotropy. The G389R polymor-
hism of the 1-adrenergic receptors is located within a
s-coupling domain (26), and 1R389 couples to adenylyl
yclase better than 1G389, resulting in enhanced 1-
drenergic receptor activity.
The ADRA2C-Del322-325 and ADRB1-G389R poly-
orphisms act synergistically, because both norepinephrine
elease and 1-adrenergic receptor activity are simulta-
eously enhanced (23). Indeed, coexistence of these 2
enetic variables is associated with an increased risk for
eart failure or for its progression (23). Accordingly, we
ested the hypothesis that in our study population this
ombination would be associated with increased reflex
utonomic activity by comparing subjects with the
DRA2C-Del322-325 and/or homozygous for ADRB1-
389 with subjects with the remaining genotypes, and
ndeed we observed a greater baroreceptor responsiveness in
he first group.
These novel genetic findings are intriguing but prelimi-
ary. They should be accepted with caution and regarded as
 working hypothesis, while we pursue confirmation in
ifferent and larger founder populations.
tudy limitations. The main limitation is represented by
he relatively small number of individuals in whom we could
ssess BRS both in the absence and presence of BB. This
elates to the objective difficulty of convincing patients
ithout symptoms, all working people, to spend 4 days in or
ear the hospital to undergo the entire study. The limited
umber of asymptomatic patients depends on the already
emonstrated high clinical severity of the A341V mutation,
o that 80% of the MCs have symptoms (2). The severity
f the A341V mutation is not related to the South African
amilies, because we confirmed it in patients with different
thnic backgrounds (27). In contrast, the rigorous selection
f study subjects (all carriers of the same mutation), the
imitation of BRS analysis to the group without age influ-
nce, and the performance of the study both on and off BB
herapy are all points of strength. Furthermore, it is reas-
uring that for the differences observed statistical signifi-
ance was reached without a large study population.
mplications. The present study has identified a mecha-
ism that helps explain why individuals carrying the same
utation producing the most common variant of LQTS,
QT1, might be more or less likely to suffer cardiac events.
his finding provides a direct link between the wide range
f autonomic responses present in normal individuals and
rrhythmic risk and also suggests a genetic origin for this
ariability.
A novel concept arises from our study. Some individuals
ight inherit a disease-causing mutation (e.g., a LQTS
utation such as KCNQ1-A341V). The same individuals
ight inherit certain specific and relatively common gene
ariants (e.g., the adrenoreceptor polymorphisms investi-
ated in our study). The genetic transmissions of the LQTS
utations and of the adrenoreceptor polymorphisms arebviously independent of each other. The coexistence of aQTS mutation with a polymorphism creating a genetic
ropensity toward brisk autonomic reflexes, a combination
hat our data indicate increases arrhythmic risk, is simply
he play of chance.
We find especially intriguing the fact that the same change
n an autonomic marker, a relatively low BRS, might predict
ncreased risk in patients with ischemic heart disease and be
ssociated with a lower probability of being symptomatic in
atients with LQT1. This highlights the predictive value of
ccurately determined autonomic markers but also implies a
pecific physiologic interaction with the underlying cardiac
bnormality, an interaction that becomes easily apparent pro-
ided that the different arrhythmogenic mechanisms involved
n diverse cardiac diseases are recognized.
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